H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Alnylam (ALNY) to $570 from $500 and keeps a Buy rating on the shares. The firm says the company’s strong commercial execution and pipeline progress drove upward revisions to its 2025 guidance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma: Strong Commercial Performance and Promising Pipeline Drive Buy Rating
- Alnylam Pharma: Strong Growth Prospects and Transition to Profitability Support Buy Rating
- Alnylam price target raised to $475 from $348 at JPMorgan
- Coinbase downgraded, Spotify upgraded: Wall Street’s top analyst calls
- Alnylam upgraded to Peer Perform from Underperform at Wolfe Research